Originally Aired: June 13, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Influenza A virus select IAV) utilizes a multivalent binding strategy to the host cell, binding its trimeric spike protein hemagglutinin select HA) to sialic acid present on the cellular membrane. For this reason, IAV has served as a model system to study multivalent ligand-receptor binding events, resulting in the discovery of potent bi-, tri-, and multivalent inhibitor compounds. To quantify the affinities between these compounds and their targets and obtain affinity constants, researchers often use technologies such as SPR, ITC, or NMR, which require high sample consumption. This is problematic since compounds that require a precise architecture, or an elaborate chemical synthesis can only be obtained at low scale. Additionally, the immobilization of one of the binding partners on solid surfaces, an environment far from native conditions, poses a challenge as viral proteins should be used in conditions that mimic the surface topology of the virus.
In this GEN webinar, we will learn from Dr. Daniel Lauster, who, when faced with many of the challenges described above, utilized MicroScale Thermophoresis select MST) to measure the interaction between more than 100 novel non-toxic multivalent nanoparticle-conjugates and intact IAV in solution with as little as nanomoles of nanoparticles. Additionally, we will hear from Dr. Matthias Molnar how MST is becoming scientists’ first choice for the characterization of molecular interactions thanks to its flexible throughput, low sample consumption, and measurements in solution or in close to native conditions.
A live Q&A session followed the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Daniel Lauster, PhD
Postdoctoral Researcher
Freie University, Berlin
Matthias Molnar, PhD
Product Manager
NanoTemper Technologies
